AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,376.50GBp
5:44am EDT
Price Change (% chg)

91.50p (+2.13%)
Prev Close
4,285.00p
Open
4,304.00p
Day's High
4,384.50p
Day's Low
4,293.50p
Volume
939,783
Avg. Vol
2,320,535
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.36
Market Cap (Mil.): £54,170.24
Shares Outstanding (Mil.): 1,262.59
Dividend: 53.10
Yield (%): 3.96

Financials

  AZN.L Industry Sector
P/E (TTM): 44.35 32.90 33.74
EPS (TTM): 0.97 -- --
ROI: 5.03 18.79 18.03
ROE: 8.94 19.42 18.77
Search Stocks

Healthcare stocks lift UK's FTSE 100

* FTSE 100 up 0.2 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Miners lag after weak Chinese data By Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. The blue-chip FTSE 100 index was up by 0.2 percent, or 10.83 points, at 6,766.31 points in early trading, approaching three-week highs touched

4:40am EDT

AstraZeneca and Mitsubishi Tanabe link on diabetes research

LONDON - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.

20 Aug 2014

AstraZeneca and Mitsubishi Tanabe link on diabetes research

LONDON, Aug 20 - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.

20 Aug 2014

U.S. clears AstraZeneca over heart drug trial

LONDON - The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects.

19 Aug 2014

UPDATE 2-U.S. clears AstraZeneca over heart drug trial

* Company hopes for new data in Dec to support expanded use

19 Aug 2014

U.S. clears AstraZeneca over heart drug trial

LONDON, Aug 19 - AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.

19 Aug 2014

BRIEF-AstraZeneca announces positive results for new antibiotic

* Announces positive top-line results from phase III programme of CAZ-AVI

19 Aug 2014

UPDATE 1-AstraZeneca gets pipeline boost from good gout drug results

LONDON, Aug 13 - AstraZeneca, which fended off a $118 billion takeover approach from Pfizer in May, reported positive results for an experimental gout drug on Wednesday that could boost its sales modestly.

13 Aug 2014

AstraZeneca reports positive results for gout combination therapy

LONDON, Aug 13 - British drugmaker AstraZeneca said on Wednesday that test results indicated that lesinurad, a selective uric acid re-absorption inhibitor, used in combination could be a potential treatment for gout.

13 Aug 2014

Pfizer bid for GSK "has some merits", says Berenberg

LONDON - Could Pfizer acquire GlaxoSmithKline as a "plan B" after failing to land AstraZeneca ? It would be a stretch but not totally impossible, according to analysts at Berenberg Bank.

01 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks